FDA Fast-Tracks AbbVie’s New Lung Cancer Therapy Emrelis For Tough Lung Cancer Cases

All NewsMay 14, 2025

FDA grants accelerated approval to AbbVie’s Emrelis for c-Met overexpressing NSCLC; siRNA partnership with ADARx includes $335 million upfront.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent